Pag-aaral pangklinika para sa Lymphoma sa Minnesota
14 pag-aaral para sa Lymphoma ang naghahanap ng mga kalahok sa mga site sa Minnesota.
Mga Lungsod sa Minnesota
Opisyal na teksto ng pag-aaral (English)
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
- Mayo Clinic Health Systems-Mankato, Mankato
- Mayo Clinic in Rochester, Rochester
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT03418038CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- University of Minnesota/Masonic Cancer Center, Minneapolis
Nagre-recruitPhase 1/2
12 Months – 21 Years · Lahat ng kasarian · Na-update Set 11, 2026 · NCT04870944Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Rochester
Nagre-recruitPhase 3
Edad 18 hanggang 18 · Lahat ng kasarian · Na-update Set 8, 2026 · NCT07509151Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Mayo Clinic, Rochester
Nagre-recruitPhase 1/2
Edad 12 pataas · Lahat ng kasarian · Na-update Set 3, 2026 · NCT04588922Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Mayo Clinic, Clinical Trials Referral Office, Rochester
Nagre-recruitPhase 1/2
Edad 13 hanggang 90 · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT06533579A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Mayo Clinic Rochester, Rochester
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 4, 2026 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- Mayo Clinic, Rochester
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 13, 2026 · NCT04792489Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
- Masonic Cancer Center at University of Minnesota, Minneapolis
Nagre-recruitPhase 2
Hanggang edad 60 · Lahat ng kasarian · Na-update Hun 25, 2026 · NCT03314974CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Mayo Clinic, Rochester
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 16, 2026 · NCT03328078Dietary and Topical Magnesium Replacement or Supplementation in Patients With Lymphoma
- Mayo Clinic in Rochester, Rochester
Nagre-recruitMaagang Phase 1Malugod na tinatanggap ang malusog na boluntaryo
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 16, 2026 · NCT05294367BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
- Mayo Clinic, Rochester
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 20, 2026 · NCT06854003cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Allina Health Cancer Institute, Minneapolis
- Mayo Clinic, Rochester
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 40 pataas · Lahat ng kasarian · Na-update Ene 20, 2026 · NCT05366881Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
- Fairview Southdale Hospital, Edina
- Hennepin County Medical Center, Minneapolis
- Monticello Cancer Center, Monticello
- at 5 pa
Nagre-recruitPhase 3Malugod na tinatanggap ang malusog na boluntaryo
Edad 18 pataas · Lahat ng kasarian · Na-update Ene 13, 2026 · NCT05006482WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
- Mayo Clinic in Rochester, Rochester
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 15, 2025 · NCT07058064Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.